FrancophonIA/ELRC3.0 huggingface dataset:
English: In studies in treatment-naïve patients, Symtuza was associated with a lower impact on the estimated glomerular filtration rate by Cockcroft-Gault method compared to control group (DRV/COBI+F/TDF).
Slovenian: V študijah s predhodno nezdravljenimi bolniki je zdravilo Symtuza le malo vplivalo na ocenjeno hitrost glomerulne filtracije po Cockcroft-Gaultovi formuli v primerjavi s kontrolno skupino (DRV/COBI+F/TDF).
English: • darunavir, an anti-HIV medicine known as a protease inhibitor
Slovenian: • darunavir, zdravilo proti virusu HIV, znano kot zaviralec proteaze
English: Tenofovir is eliminated from the body by the kidneys by both glomerular filtration and active tubular secretion.
Slovenian: Tenofovir se izloča iz telesa skozi ledvice z glomerularno filtracijo in z aktivno tubulno sekrecijo.
English: No pharmacokinetic data are available for emtricitabine and tenofovir alafenamide during pregnancy.
Slovenian: Farmakokinetični podatki za emtricitabin in alafenamidtenofovirat med nosečnostjo niso na voljo.
English: Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for > 80% of an oral dose.
Slovenian: Presnova je glavna pot izločanja alafenamidtenofovirata pri človeku in predstavlja > 80% peroralnega odmerka.
English: ART-experienced patients
Slovenian: Bolniki, z izkušnjami z ART
English: Symtuza is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products (see section 4.5).
Slovenian: Zdravilo Symtuza je indicirano za celovito zdravljenje okužbe z virusom HIV-1 in se ga ne sme dajati sočasno z drugimi protiretrovirusnimi zdravili (glejte poglavje 4.5).
English: Some patients taking anti-HIV medicines may develop a bone disease called osteonecrosis (bone damage caused by loss of blood supply to the bone).
Slovenian: Pri nekaterih bolnikih, ki imajo protiretrovirusno zdravljenje, lahko pride do bolezni kosti, ki se imenuje osteonekroza (odmiranje kostnega tkiva, ki je posledica zmanjšane prekrvavitve kosti).
English: Some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour).
Slovenian: Poročali so o nekaterih primerih nevroloških motenj s kasnejšim začetkom (hipertonija, konvulzije, nenormalno vedenje).
English: Changes in measures of bone mineral density
Slovenian: Spremembe v meritvah mineralne kostne gostote
English: A potential risk of nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir alafenamide cannot be excluded (see section 5.3).
Slovenian: Pri kronični izpostavljenosti majhnim odmerkom tenofovirja zaradi uporabe alafenamidtenofovirata ni mogoče izključiti tveganja za nefrotoksično delovanje (glejte poglavje 5.3).
English: Darunavir is extensively metabolised by the hepatic CYP system and almost exclusively by isozyme CYP3A4.
Slovenian: Darunavir se obsežno presnavlja z jetrnim encimskim sistemom CYP, in sicer skoraj izključno z izoencimom CYP3A4.
English: Because there is a lower tenofovir exposure in rats and mice after the administration of tenofovir alafenamide compared to tenofovir disoproxil, carcinogenicity studies and a rat peri-postnatal study were conducted only with tenofovir disoproxil.
Slovenian: Zaradi manjše izpostavljenosti tenofovirju pri podganah in miših po odmerjanju alafenamidtenofovirata v primerjavi z odmerjanjem dizoproksiltenofovirata so študije kancerogenosti in perinatalne ter postnatalne študije na podganah izvedli samo z dizoproksiltenofoviratom.
English: Renal excretion of intact tenofovir alafenamide is a minor pathway with less than 1% of the dose eliminated in urine.
Slovenian: Izločanje nespremenjenega alafenamidtenofovirata preko ledvic je manj pomembno, saj se z urinom izloči manj kot 1% odmerka.
English: What Symtuza is and what it is used for What you need to know before you take Symtuza How to take Symtuza
Slovenian: Kaj je zdravilo Symtuza in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Symtuza Kako jemati zdravilo Symtuza Možni neželeni učinki
English: Patients co-infected with HIV and HBV who discontinue Symtuza should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.
Slovenian: Bolnike s sočasno okužbo z virusom HIV in virusom hepatitisa B in so prekinili zdravljenje z zdravilom Symtuza, je treba skrbno spremljati tako klinično kot laboratorijsko še najmanj nekaj mesecev po zaključku zdravljenja.
English: Tenofovir alafenamide is minimally metabolised by CYP3A4.
Slovenian: Alafenamidtenofovirat se v manjši meri presnavlja s CYP3A4.
English: Patients receiving Symtuza or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.
Slovenian: Pri bolnikih, ki prejemajo zdravilo Symtuza ali katero koli drugo protiretrovirusno zdravilo, lahko še naprej prihaja do oportunističnih okužb in drugih zapletov okužbe z virusom HIV, zato morajo zdravniki z izkušnjami z zdravljenjem bolnikov s HIV in povezanimi okužbami, le te še naprej skrbno klinično spremljati.
English: Following oral administration of Symtuza, the median terminal elimination half-life of emtricitabine is 17.2 hours.
Slovenian: Po peroralnem odmerjanju zdravila Symtuza je mediani končni razpolovni čas izločanja emtricitabina 17,2 ure.
English: Concomitant use of PDE-5 inhibitors for the treatment of erectile dysfunction with Symtuza should be done with caution.
Slovenian: Pri sočasni uporabi zdravila Symtuza in zaviralcev PDE-5 za zdravljenje motenj erekcije je potrebna previdnost.
English: At peak plasma concentration, the mean plasma to blood drug concentration ratio was approximately 1.0 and the mean semen to plasma drug concentration ratio was approximately 4.0.
Slovenian: Pri najvišji koncentraciji v plazmi je bilo povprečje razmerja med koncentracijo zdravila v plazmi in krvi približno 1,0, povprečje razmerja med koncentracijo zdravila v spermi in plazmi pa je bilo približno 4,0.
English: - Digoxin (to treat certain heart disorders) - Clarithromycin (antibiotic) - Clotrimazole, fluconazole, Isavuconazole, itraconazole, posaconazole, (for treating fungal infections).
Slovenian: - digoksin (za določene srčne bolezni) - klaritromicin (antibiotik) - klotrimazol, flukonazol, izavukonazol, itrakonazol, posakonazol (za zdravljenje glivičnih okužb).
English: When used for birth control, non-hormonal contraception methods are recommended.
Slovenian: Če navedena zdravila potrebujete za kontracepcijo, priporočamo uporabo drugih, nehormonskih kontracepcijskih metod.
English: Since darunavir and cobicistat are highly bound to plasma proteins, it is unlikely that they will be significantly removed by haemodialysis or peritoneal dialysis.
Slovenian: Ker se darunavir in kobicistat v veliki meri vežeta na beljakovine v plazmi, ni verjetno, da bi s hemodializo ali peritonealno dializo lahko iz telesa odstranili pomembno količino teh dveh učinkovin.
English: Symtuza should not be administered concomitantly with medicinal products requiring pharmacokinetic enhancement with ritonavir or cobicistat.
Slovenian: Zdravila Symtuza se ne sme dajati sočasno z zdravili, pri katerih je potrebna farmakokinetična okrepitev z ritonavirjem ali kobicistatom.
English: • muscle pain, muscle cramps or weakness
Slovenian: • bolečina v mišicah, mišični krči ali šibkost mišic
English: Tenofovir alafenamide is active against hepatitis B virus (HBV).
Slovenian: Alafenamidtenofovirat deluje proti virusu hepatitisa B.
English: Human experience of acute overdose with Symtuza is limited.
Slovenian: Izkušnje z akutnim prevelikim odmerjanjem zdravila Symtuza pri ljudeh so omejene.
English: The below list of examples of drug drug interactions is not comprehensive and therefore the label of each drug that is co-administered with Symtuza should be consulted for information related to the route of metabolism, interaction pathways, potential risks, and specific actions to be taken with regards to co-administration.
Slovenian: Seznam primerov medsebojnega delovanja med posameznimi učinkovinami v spodnji preglednici ni popoln, zato je treba za vsako zdravilo, ki se jemlje sočasno z zdravilom Symtuza, pregledati podatke o poti presnove, interakcijah, morebitnih tveganjih in posebnih ukrepih ob sočasni uporabi.
English: At Week 96, the median change in eGFRCG was -5.2 mL/min with D/C/F/TAF.
Slovenian: V 96. tednu je bila mediana sprememba eGFRCG v skupini D/C/F/TAF -5,2 ml/min.
English: The mean increase from baseline in CD4+ cell count at Week 48 was 224 cells/mm
Slovenian: Povprečno povečanje števila celic CD4+ od izhodišča do 48. tedna je bilo 224 celic/mm
English: If there is evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients using Symtuza, interruption or discontinuation of treatment should be considered promptly (see section 5.3).
Slovenian: Če pri bolnikih, ki se zdravijo z zdravilo Symtuza, opazite znake novih ali poslabšanje že obstoječih motenj delovanja jeter (vključno s klinično pomembnim povečanjem koncentracij jetrnih encimov in/ali simptomi, kot so utrujenost, anoreksija, navzea, zlatenica, temno obarvan urin, boleča jetra, hepatomegalija), je nemudoma treba razmisliti o prekinitvi ali ukinitvi zdravljenja (glejte poglavje 5.3).
English: A safe and effective dose of sildenafil for the treatment of pulmonary arterial hypertension co-administered with Symtuza has not been established.
Slovenian: Varnega in učinkovitega odmerka sildenafila za zdravljenje pljučne arterijske hipertenzije skupaj z zdravilom Symtuza niso ugotovili.
English: Emerging Resistance in AMBER and EMERALD Trial (Week 96)
Slovenian: Pojavljanje odpornosti na zdravila v študijah AMBER in EMERALD (po 96 tednih)
English: Co-administration with the following medicinal products due to the potential for loss of therapeutic effect (see section 4.5): - carbamazepine, phenobarbital, phenytoin - rifampicin
Slovenian: Sočasno zdravljenje s katerim koli od naslednjih zdravil zaradi možne izgube terapevtskega učinka (glejte poglavje 4.5): - karbamazepin, fenobarbital, fenitoin
English: 6 cells/L),
Slovenian: 6 celic/l).
English: In vitro binding of tenofovir to human plasma proteins is < 0.7% and is independent of concentration over the range of 0.01-25 mcg/mL.
Slovenian: In vitro je vezava tenofovirja na humane plazemske beljakovine manjša od 0,7% in je neodvisna od koncentracije v razponu od 0,01-25 µg/ml.
English: Symtuza should not be initiated in patients with eGFRCG < 30 mL/min, as there are no data available regarding the use of Symtuza in this population (see sections 5.1 and 5.2).
Slovenian: Zdravljenja z zdravilom Symtuza se ne sme uvesti bolnikom z eGFRCG < 30 ml/min, saj za to skupino bolnikov ni na voljo podatkov o uporabi zdravila Symtuza (glejte poglavji 5.1 in 5.2).
English: For emtricitabine, the Cmax was 1.26-fold higher in a fasted condition, while the AUC was comparable in fed and fasted condition.
Slovenian: Cmax emtricitabina je bila 1,26-krat večja po odmerjanju zdravila na tešče, AUC pa je bila primerljiva v pogojih zaužitja zdravila po hrani in na tešče.
English: Symtuza and sofosbuvir, sofosbuvir/ledipasvir, or daclatasvir can be used concomitantly without dose adjustment
Slovenian: Zdravilo Symtuza in sofosbuvir, sofosbuvir/ledipasvir, ali daklatasvir se sočasno lahko uporablja brez prilagoditve odmerka.
English: Table 5:
Slovenian: Preglednica 5:
English: Symtuza may decrease boceprevir plasma concentrations.
Slovenian: Zdravilo Symtuza lahko znižuje koncentracijo boceprevirja v plazmi.
English: (P-gp, BCRP and/or OATP1B1/3 inhibition)
Slovenian: (zaviranje P-gp , BCRP in/ali OATP1B1/3)
English: There are no adequate and well controlled trials with darunavir, cobicistat, emtricitabine, or tenofovir alafenamide, alone or in combination, in pregnant women.
Slovenian: Ustreznih in dobro nadzorovanih preskušanj z darunavirjem, kobicistatom, emtricitabinom in alafenamidtenofoviratom v monoterapiji ali v kombinaciji pri nosečnicah niso izvedli.
English: Upon co-administration with the moderate CYP3A inducer probe efavirenz, tenofovir alafenamide exposure was not significantly affected.
Slovenian: Po sočasnem odmerjanju z efavirenzom, testnim zmernim induktorjem CYP3A, se izpostavljenost alafenamidtenofoviratu ni bistveno sprememnila.
English: During the darunavir/ritonavir clinical development program (N = 3,063), hepatitis was reported in 0.5% of patients receiving combination antiretroviral therapy with darunavir/ritonavir.
Slovenian: V kliničnem preskušanju zdravil darunavirj/ritonavirj (n = 3.063), so o hepatitisu poročali pri 0,5% bolnikov, ki so prejemali kombinirano protiretrovirusno zdravljene s kombinacijo darunavirja/ritonavirja.
English: Five subjects were discontinued from the study due to efficacy related reasons per investigator's assessment (physician decision), of which 3 had last on treatment HIV-1 RNA <50 copies/mL.
Slovenian: Pet preiskovancev so izključili iz študije zaradi neustrezne učinkovitosti zdravila po presoji raziskovalca (zdravnikova odločitev).Med njimi so imeli trije preiskovanci med zdravljenjem zadnje izmerjeno virusno breme HIV-1 RNK <50 kopij/ml.
English: How to take Symtuza
Slovenian: Kako jemati zdravilo Symtuza
English: No clinically relevant differences in tenofovir alafenamide, or tenofovir pharmacokinetics were observed between healthy subjects and patients with severe renal impairment (eGFRCG > 15 but < 30 mL/min) in studies of tenofovir alafenamide.
Slovenian: Klinično pomembnih razlik v farmakokinetičnih lastnostih alafenamidtenofovirata ali tenofovirja med zdravimi osebami in bolniki s hudo okvaro ledvic (eGFRCG > 15 in < 30 ml/min) v študijah z alafenamidtenofoviratom niso opazili.
English: A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 15 and 40 times greater, respectively, than those expected after administration of Symtuza.
Slovenian: Minimalna infiltracija histiocitov je bila v očesnem tkivu psov prisotna pri izpostavljenosti alafenamidtenofoviratu in tenofovirju, ki je približno 15-krat oziroma 40-krat večja od pričakovane po odmerjanju zdravila Symtuza.
English: In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
Slovenian: Pri bolnikih z napredovalo boleznijo jeter ali cirozo prekinitev zdravljenja ni priporočljivo, ker lahko kasnejše poslabšanje hepatitisa vodi v jetrno dekompenzacijo.
English: Lipid Parameter Baseline Median
Slovenian: Lipidni parameter Izhodiščna mediana vrednost
English: Bone toxicity was observed as reduced bone mineral density in rats and dogs at tenofovir exposures at least four times greater than those expected after administration of Symtuza.
Slovenian: Toksično delovanje na kosti so opažali kot zmanjšano mineralno gostoto kosti pri podganah in psih pri izpostavljenostih tenofovirju, ki so bile vsaj štirikrat večje od izpostavljenosti, ki je pričakovana pri odmerjanju zdravila Symtuza.
English: Tenofovir has a median plasma half-life of approximately 32 hours.
Slovenian: Mediani končni razpolovni čas izločanja tenofovirja iz plazme je približno 32 ur.
English: In vitro and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP-mediated interactions involving emtricitabine with other medicinal products is low.
Slovenian: Študije in vitro in klinične framakokinetične študije medsebojnega delovanja zdravil so pokazale, da obstaja le majhna možnost za z encimi CYP posredovane interakcije emtricitabina z drugimi zdravili.
English: • if you notice any symptoms of infection (e.g. swollen lymph nodes and fever).
Slovenian: • če opazite kakršne koli simptome okužbe (npr. otekle bezgavke ali zvišano telesno temperaturo).
English: White, high density polyethylene (HDPE) bottle with a silica gel desiccant (contained in a separate sachet or canister) fitted with polypropylene (PP) child resistant closure with induction seal.
Slovenian: Bela plastenka iz polietilena velike gostote (HDPE) s sušilnim sredstvom iz silikagela(v posebni vrečki ali vsebniku), opremljen z za otroke varno polipropilensko (PP) zaporko in indukcijskim pečatom.
English: This subject harbored a K103N mutation at screening, indicating transmitted NNRTI resistance.
Slovenian: Ta oseba je je imela že ob začetnem presejalnem obisku prisotno mutacijo K103N, kar kaže na prenos odpornosti za nenukleozidne zaviralce reverzne transkriptaze NNRTI.
English: In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening.
Slovenian: Pri nekaterih bolnikih z napredovalo boleznijo jeter ali cirozo lahko prenehanje zdravljenja povzroči poslabšanje hepatitisa, ki je lahko življenjsko nevarno.
English: The median change in eGFRCG was -5.5 mL/min with D/C/F/TAF and -12.0 mL/min with D/C+F/TDF (p < 0.001).
Slovenian: Mediana sprememba ocenjene hitrosti glomerulne filtracije (eGFRCG) je bila -5,5 ml/min v skupini D/C/F/TAF in -12,0 ml/min v skupini D/C+F/TDF (p < 0,001).
English: HIV-1 isolates with reduced susceptibility to tenofovir alafenamide express a K65R mutation in HIV-1 RT; in addition, a K70E mutation in HIV-1 RT has been transiently observed.
Slovenian: Izolati virusa HIV-1 z zmanjšano občutljivostjo na alafenamidtenofovirat izražajo mutacijo K65R reverzne transkriptaze virusa HIV-1, prehodno pa so opažali tudi mutacijo K70E reverzne transkriptaze virusa HIV-1.
English: Cobicistat inhibits the transporters p-glycoprotein (P-gp), BCRP, MATE1, OATP1B1 and OATP1B3.
Slovenian: Kobicistat zavira prenašalce P-glikoprotein (P-gp), BCRP, MATE1, OATP1B1 in OATP1B3.
English: In vivo, darunavir resistance-associated mutations (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V and L89V) in HIV-1 protease were derived from clinical trial data of ART-experienced patients, all of whom were protease inhibitor experienced.
Slovenian: Podatki o mutacijah, povezanih z odpornostjo na darunavir (mutacijah V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V in L89V) v genu za proteazo virusa HIV-1, ki so jih pridobili in vivo, izhajajo iz kliničnih preskušanj z bolniki, ki so predhodno že prejemali protiretrovirusno zdravljenje, in sicer so med njimi vsi že prejemali zaviralce proteaze.
English: Cobicistat is 97% to 98% bound to human plasma proteins and the mean plasma to blood-drug concentration ratio was approximately 2.
Slovenian: Kobicistat se v 97-98% veže na plazemske beljakovine, povprečje razmerja med koncentracijo zdravila v plazmi in krvi pa je približno 2.
English: Rifabutin Rifapentine
Slovenian: rifabutin rifapentin
English: • If you notice within 12 hours of the time you usually take Symtuza, you must take the tablet immediately, with food.
Slovenian: • Če je minilo manj kot 12 ur od takrat, ko običajno vzamete zdravilo Symtuza, morate tableto vzeti takoj, in sicer s hrano.
English: Therapy should be initiated by a physician experienced in the management of HIV-1 infection.
Slovenian: Terapijo sme uvesti samo zdravnik z izkušnjami z zdravljenjem okužbe z virusom HIV-1.
English: Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism.
Slovenian: Zaviranje presnove preko CYP3A s kobicistatom poveča sistemsko izpostavljenost substratom CYP3A, kot je darunavir, ki ima zaradi presnove, odvisne od CYP3A, omejeno biološko uporabnost in krajši razpolovni čas.
English: It is not known whether darunavir, cobicistat, or tenofovir alafenamide are excreted in human milk.
Slovenian: Ni znano, ali se darunavir, kobicistat in alafenamidtenofovirat izločajo v materino mleko.
English: The film-coating contains polyethylene glycol (macrogol), polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide and yellow ferric oxide.
Slovenian: Filmska obloga vsebuje polietilenglikol (makrogol), polivinilalkohol (delno hidroliziran), smukec, titanov dioksid in rumeni železov oksid.
English: Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%).
Slovenian: Emtricitabin se primarno izloča skozi ledvice, pri čemer so celotni odmerek emtricitabina izolirali deloma v urinu (približno 86%) in deloma v blatu (približno 14%).
English: Although most rashes are mild and disappear after a while as treatment is continued, a rash can occasionally be severe or potentially life-threatening.
Slovenian: Izpuščaj je običajno blag in sčasoma izzveni ob nadaljevanju zdravljenja, v nekaterih primerih pa je izpuščaj hud in je lahko življenjsko nevaren.
English: In the Phase 3 trial of Symtuza in treatment-naïve patients, increases in serum creatinine and decreases in eGFRCG occurred at the first on-treatment assessment (Week 2) and remained stable through 96 weeks.
Slovenian: V preskušanju faze 3 z zdravilom Symtuza pri predhodno nezdravljenih bolnikih se je povečala koncentracija kreatinina v serumu in zmanjšala ocenjena hitrost glomerulne filtracije (eGFRCG) pri prvi meritvi med zdravljenjem (po 2 tednih), vrednost je nato ostala stabilna do konca 96. tedna.
English: These findings were attributed to the immaturity of the liver enzymes and of the blood brain barrier.
Slovenian: Te ugotovitve so pripisali nerazvitosti jetrnih encimov in hematoencefalne bariere.
English: Methadone
Slovenian: metadon
English: There is an increased potential for sildenafil-associated adverse events (including visual disturbances, hypotension, prolonged erection and syncope).
Slovenian: Pri uporabi te kombinacije obstaja povečana verjetnost za pojav s sildenafilom povezanih neželenih dogodkov (vključno z motnjami vida, hipotenzijo, podaljšanim časom erekcije in sinkopo).
English: In the study GS-US-292-0106, the efficacy, safety, and pharmacokinetics of emtricitabine and tenofovir alafenamide were evaluated in an open-label study in which 50 HIV-1 infected, treatment-naïve adolescents received emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet.
Slovenian: V študiji GS-US-292-0106 so ocenjevali učinkovitost, varnost in farmakokinetiko emtricitabina in alafenamidtenofovirata v odprti študiji, v kateri je 50 predhodno nezdravljenih mladostnikov z okužbo z virusom HIV-1 prejemalo emtricitabin in alafenamidtenofovirat (10 mg) skupaj z elvitegravirjem in kobicistatom v obliki tablete s fiksno kombinacijo odmerkov.
English: HIV-1 isolates with the K65R mutation have low-level reduced susceptibility to abacavir, emtricitabine, tenofovir, and lamivudine.
Slovenian: Pri izolatih virusa HIV-1 z mutacijo K65R se je pojavljala nizka stopnja zmanjšane občutljivosti za abakavir, emtricitabin, tenofovir in lamivudin.
English: Among 1,968 treatment-experienced patients receiving darunavir co-administered with ritonavir 600/100 mg twice daily, 236 patients were co-infected with hepatitis B or C. Co-infected patients were more likely to have baseline and treatment emergent hepatic transaminase elevations than those without chronic viral hepatitis.
Slovenian: Med 1.968 bolniki, ki so že bili zdravljeni s protiretrovirusnimi zdravili in so prejemali darunavir skupaj z ritonavirjem (600/100 mg dvakrat na dan), jih je bilo 236 okuženih tudi s hepatitisom B ali C. Pri bolnikih s sočasno okužbo je povišanje koncentracije jetrnih aminotransferaz bolj verjetno (ob izhodišču in med zdravljenjem) kot pri bolnikih brez kroničnega virusnega hepatitisa.